Telix's stock price has fallen significantly after news from the FDA, with some reports indicating a 20% decline and others stating a 31% plunge. The drop has led investors to reassess the company, one of the biggest biotechnology success stories on the ASX. The reason for the decline appears to be related to an FDA update and a subpoena from the SEC, although the exact impact of these developments is unclear.